Celator(R) Pharmaceuticals Announces Appointment of Les Mintzmyer as Vice-President Manufacturing and Technical Operations

Celator Pharmaceuticals. Inc. Logo

EWING, N.J., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the appointment of industry veteran Les Mintzmyer as vice-president, manufacturing and technical operations. Mintzmyer will be responsible for optimizing the Company's production, supply chain logistics, customer service, quality, and regulatory compliance, while working closely with the Company's contract supply and manufacturing organizations in the planning and introduction of new products.

"We are excited to have Les join the Celator management team," said Scott Jackson, chief executive officer of Celator Pharmaceuticals. "Les has a significant amount of manufacturing experience, which will be important as the company advances CPX-351 as a new treatment for acute myeloid leukemia, and possibly other hematologic malignancies, and prepares for potential commercialization. He will make an immediate and substantive contribution to our success."

Mintzmyer joins Celator from Laureate Biopharmaceutical Services, where he was vice-president of manufacturing operations. He and his team were responsible for delivering a broad spectrum of service offerings for contract clients, ranging from early development through commercial products.

Prior to joining Laureate, Mintzmyer held senior positions at Avid Bioservices (Peregrine Pharmaceuticals), ImClone Corporation, Genentech, Inc., and Bristol-Myers Squibb Corporation. Mintzmyer holds an undergraduate degree in biology/chemistry from the University of Nebraska at Kearney, as well as undergraduate and master's degrees in chemical engineering from Colorado State University.

"I am very excited to be joining Celator Pharmaceuticals and applying my twenty-seven years of experience toward advancing CPX-351, Celator's technology platforms, and other products in the pipeline," said Mintzmyer. "With a Phase 3 study in acute myeloid leukemia currently enrolling, I will work to position Celator for the potential commercialization of CPX-351, as well as other products, based upon the company's technology platforms."

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two clinical stage products, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; and preclinical stage product candidates, including CPX-571 (a liposomal formulation of irinotecan:floxuridine), and hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory. For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.

Forward-Looking Statements:

To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will" "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, our expectations regarding our development plans for and the potential efficacy and therapeutic potential of our drug candidates and other matters that could affect the commercialization of our drug candidates. Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator's Form 10-K for the year ended December 31, 2012 and other filings by the company with the U.S. Securities and Exchange Commission.

CONTACT: Media: Mike Beyer, Sam Brown, Inc. 773-463-4211, beyer@sambrown.com Investors: Beth DelGiacco, Stern Investor Relations, Inc. (212) 362-1200, beth@sternir.com

Source:Celator Pharmaceuticals. Inc.